Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.

Journal of surgical oncology - 1 Dec 2011

Kim Edward J, Zalupski Mark M

Abstract excerpt

Progression on first-line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib-resistant GIST include agents that target KIT/PDGFR with greater potency or possess broader kinase inhibition profiles including VEGFR. To circumvent secondary mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Neoplasms
Share to Gastrointestinal Stromal Tumors
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Share to Pyrroles

Share to Receptors, Platelet-Derived Growth Factor

Share to Sunitinib

Share to Thiazoles

Source

Identifiers

PMID: 22069175
DOI: 10.1002/jso.21872

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.PMID 22069175Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Translational insights into gastrointestinal stromal tumor and current clinical advances.Semantic proximity Read ↗

Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Semantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

New targets and therapies for gastrointestinal stromal tumors.Semantic proximity Read ↗

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions.Semantic proximity Read ↗

Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.Semantic proximity Read ↗

The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.